Developing renal allograft surveillance strategies – urinary biomarkers of cellular rejection

Table 1 Diagnostic performance of urinary CXCR3 chemokine proteins

Biomarker				Acute cellular rejection ^g					Subclinical rejection
CXCL9	Population	Study Design	n ^{a, b}	AUC	Sensitivity	Specificity	Ref	AUC	Sensitivity	Specificity	Ref
	Multi-center ^c	Prospective, observational cohort	280	0.86	0.87	0.82	26	Subclinical group too small for AUC
	Single center	Prospective, observational cohort	69	NR	0.93	0.89	44	Subclinical group too small for AUC ^e
	Single center	Case control	125	0.87	0.86	0.80	45	Subclinical group too small for AUC
	Two centers	Case control	88					0.78	0.86	0.64	27
	Single center	Case control	113	0.92	0.85	0.90	42
	Single center	Case control	99	NR	0.80	0.94	43
	Single center	Case control	201	0.90	0.84	0.83	46
	Single center ^f	Case control	213	0.91	0.90	0.84	47
CXCL10	Population	Study Design	n ^{a, b}	AUC	Sensitivity	Specificity	Ref	AUC	Sensitivity	Specificity	Ref
	Multi-center ^c	Prospective, observational cohort	280	0.77	0.74	0.86	26	Subclinical group too small for AUC
	Single center	Prospective, observational cohort	213	0.74	0.63	0.80	25	0.69	0.61	0.72	25
	Two centers	Case control	88					0.79	0.68	0.90	27
	Single center	Case control	91	0.84	0.78	0.59	28	0.85	0.73	0.73	28
	Single center ^d	Case control	51	0.88	0.77	0.60	52	0.81	0.59	0.67	52
	Single center	Case control	54					0.77 ^e	0.62	0.95	48
	Single center ^c	Case control	125	0.83	0.80	0.76	45	Subclinical group too small for AUC
	Single center	Case control	113	0.93	0.89	0.81	42
	Single center	Case control	99	NR	0.86	0.91	43
	Single center	Case control	201	0.81	0.65	0.97	46
	Single center ^f	Case control	213	0.80	0.70	0.76	47

^a Numbers of patients (not urine numbers), some studies are confounded with repeated measures; ^b Numbers in the AUC analysis, not the overall study population; ^c Pediatric population included; ^d Pediatric population only; ^e Subclinical refers to the AUC 4-5 days prior to clinical rejection for these studies; ^f Rabant et al. performed a prospective observational study of patients with indication biopsies – the data reported here are for the TCMR sub-group analysis; ^g Rejection is scored by the Banff criteria, but the definitions used vary by study. NR not reported

ISSN: 2054-3581